Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
It’s been years since Big Pharma last witnessed a megamerger. In the late 2010s, Takeda bought Shire, AbbVie acquired Allergan, and Bristol Myers Squibb swallowed Celgene. | Combining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, cost numerous jobs, all while damaging the broader biopharma ecosystem and hurting patients, Angus Liu argues in an editorial.
TL;DRAI
AstraZeneca and Bristol Myers Squibb discussed a $400 billion mega-merger to expand US footprint. Portfolio overlap in checkpoint inhibitors, CAR-T, and ADCs poses antitrust risk, R&D pipeline disruption, and 128k job cuts with zero strategic value.
1,303 words~6 min read
